Oncology-Focused Contract Research Organization (CRO):
Contracted by biopharma to design, manage and monitor trials as well as analyze results
From Pre-Clinical to Post-Approval, SCRI Development Innovations Delivers End-to-End CRO Capabilities:
- As a part of SCRI, we leverage expert physician expertise to design and implement clinical trials to advance therapies and improve the lives of patients fighting cancer.
- We work in tandem with SCRI’s centralized Site Management Organization (SMO) to design and deliver timely site activation, patient recruitment and overall study delivery.
- Powered by Genospace’s precision medicine technology, our personalized medicine expertise informs clinical development approaches every step of the way.
- Clinical Development
- Strategic Planning & Oversight
- Clinical Monitoring
- Medical Monitoring
- Medical Writing & Publishing
- Pharmacovigilance
- Regulatory Affairs
- Data Management
- Project Management
- Biostatistics
Our Differentiators:
- Strategic Site Relationship & Expedited Start-up – We’re able to leverage existing relationships and infrastructure with SCRI sites to achieve expedited start-up in as little as 6 weeks
- Unique Personalized Medicine & Data Capabilities – SCRI’s Personalized Medicine program offers scientific consultative services to drug development partners to enrich clinical development insights
395+
- 37 Active Industry Sponsored Trials
- 8 Active Investigator Initiated Trials
65+
first-in-human trials conducted
25+
first-in-class trials conducted
CRO with Roots in Cancer since 2006
Centralized Site Management Organization (SMO):
Partner with a network of sites where physicians enroll and treat patients on clinical trials:
- SCRI’s Site Management Organization (SMO) offers operational and other centralized research support services for sites on phase I through III industry-sponsored and investigator-initiated trials.
- The SMO offers support services for trials across tumor types including highly specialized expertise in complex GI, lung, breast/gynecologic, central nervous system, genitourinary, melanoma and blood cancers. Additionally, the SMO works with FACT-accredited transplant sites to advance cellular therapy research inclusive of CAR T-Cell, CRISPR and other novel approaches.
SCRI Centralized Site Support Services
Menu Management & Accelerated Start Up
Regulatory
Budget, Contract, and Financial Services
Protocol Operations
Global Quality & Education
Technology Integration & Support
Financial Planning & Analysis
Our Differentiators:
- Rapid study activation timelines
- Community clinic-based model at SCRI sites provides access to larger numbers of patients
- Efficiencies with budget, contract, and informed consent
- Utilization of central IRBs
- Standardized SOPs and quality metrics across all SCRI sites
- Partners with the Personalized Medicine team to rapidly identify patients for trials
Personalized Medicine
Leverages real-world data to advise physicians and biopharma on clinical development and treatment planning
Leverages patient data to inform clinical development patient strategies
- Powered by cloud-based precision medicine technology developed by Genospace that transforms patient data into actionable insights
- Informs trial design, trial matching, optimal treatment recommendations for patients and population diversification
Genospace combines rich data sources with powerful technology to make biomedical data useful and usable, enabling the convergence of clinical research and clinical care.
Learn More About Genospace
Personalized Medicine Program Includes:
Site Support
- Patient-Centric Clinical Trial Matching
- Molecular Cancer Conferences: SCRI’s Molecular Tumor Boards
- MolecularHelp Consultation: On Demand Reviews of NGS Reports
- Molecular Education
- Variant Annotation
- Clinical Trial Incl/Excl Criteria
- Drug MOA sensitivity
Partner Support
- Feasibility Analysis
- Real World Data Analytics
- Data-Driven Study Design
- On Study Analytics
- Scientific Consultative Services
Clinical Trial Access
SCRI is focused on increasing access to clinical trials for community oncology clinicians and patients across our network. By partnering with key oncology stakeholders, our Access program builds system-level, inclusion-centered enhancements to trial design and implementation to proactively mitigate barriers impacting patients broadly, particularly those historically underrepresented on clinical trials.
The SCRI Access team acts across the cancer care and drug development continuum by partnering with stakeholders from the sponsor to the ground-level clinical teams to patient communities.
By establishing cross-stakeholder partnerships, SCRI Access develops an action plan based on the priorities shared by the partner – a specific clinical trial, an area of the pipeline, a particular community, among others. SCRI then develops the Access Blueprint for Action, personalized to our partner’s specific equity needs and priorities.
Our Services:
- Diversity Plan Support
- Analysis of Recruitment & Retention Strategy
- Study Design Optimization Review
- 360º Access Appraisal of Trial Experience with Access Action Plan
- On-Demand Equity Check
- End-of-Study Sponsor Summary
- Ad Hoc Access Support
